Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
Abstract Despite advances in HIV‐1 management with antiretroviral therapy, drug resistance and toxicities with multidrug regimens can result in treatment failure. Hence, there is a continuing demand for antiretroviral agents (ARVs) with novel mechanisms of action. Maturation inhibitors inhibit HIV‐1...
Saved in:
Main Authors: | Samit R. Joshi (Author), Disala Fernando (Author), Stephanie Igwe (Author), Litza McKenzie (Author), Anu S. Krishnatry (Author), Fiona Halliday (Author), Joyce Zhan (Author), Thomas J. Greene (Author), Jianfeng Xu (Author), Geraldine Ferron‐Brady (Author), Max Lataillade (Author), Sherene Min (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
by: Ying Zhang, et al.
Published: (2023) -
Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254)
by: Konstantinos Stamatopoulos, et al.
Published: (2023) -
Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
by: Anu Shilpa Krishnatry, et al.
Published: (2021) -
Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors
by: Anu Shilpa Krishnatry, et al.
Published: (2022) -
Supporting the next generation of non-communicable disease research leaders in Africa - experience of the GSK Africa NCD Open Lab
by: Juliet Addo, et al.
Published: (2020)